Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

125.10 +5.86 (+4.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharma Plc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone. 
Via Benzinga
Exposures Product Safety
UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
CEO Bruce Cozadd emphasized that Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year. 
Via Benzinga
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ): good value for what you're paying. 
Via Chartmill
In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5! 
Via The Motley Fool
Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts
Via Benzinga
Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued.
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
Via Chartmill
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a... 
Via Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
Via Chartmill
FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
Veterans: Epidiolex shows promise in treating Gulf War Illness, offering hope for those affected. Learn how it might benefit them. 
Via Benzinga
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
Via Chartmill
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
Via Benzinga
How Is The Market Feeling About Jazz Pharmaceuticals?
Via Benzinga
Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
Via Benzinga
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and... 
Via Benzinga
'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
Via Benzinga
The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
Via Benzinga
In a market where value is scarce, NASDAQ:JAZZ offers a refreshing opportunity with its solid fundamentals.
Don't overlook JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
The 3 Best Cannabis Stocks to Buy in August 2024
Although cannabis stocks have been brutalized earlier, favorable legal winds could make the sector intriguing again. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
3 Biotech Stocks to Buy on the Dip: July 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
Via InvestorPlace
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
The companies are no longer developing their drug for essential tremor treatment. 
Via Investor's Business Daily
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July. 
Via InvestorPlace
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Avicanna Exports Cannabinoids To Singapore Legally — Even Though Cannabis Is Punishable By Death In The Country
Cannabinoid-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) announced on Thursday that through its majority-owned subsidiary Santa Marta Golden Hemp the company... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 Mid-Cap Growth Rockets Trading at Deep Discounts to Their Potential
Large cap stocks are where the alpha is now, but there’s a case to be made for these undervalued mid-cap growth stocks 
Via InvestorPlace
7 Biotech Stocks to Boost Your Portfolio to Peak Health
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. 
Via InvestorPlace
3 Cannabis Stocks That Could Make Your Grandchildren Rich
These cannabis stocks offer long-term growth potential anchored by solid operational models and diversified revenue streams today. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.